The clinical content of preconception care: the use of medications and supplements among women of reproductive age

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 6 SUPPL. B, 2008, Pages

  Dunlop, Anne L ^a   Gardiner, Paula M ^b   Shellhaas, Cynthia S ^c   Menard, M Kathryn ^d   McDiarmid, Melissa A ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c Division of Maternal Fetal Medicine   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

medication; preconception; prescription; teratogen

Indexed keywords

ALUMINUM HYDROXIDE; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CARBONATE; CARBAMAZEPINE; CLEMASTINE; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAMOTIDINE; FOLIC ACID ANTAGONIST; GUAIFENESIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; KANAMYCIN; LEFLUNOMIDE; LITHIUM; MAGNESIUM HYDROXIDE; NIZATIDINE; NON PRESCRIPTION DRUG; PHENYTOIN; PSEUDOEPHEDRINE; RANITIDINE; SIMETHICONE; STREPTOMYCIN; TESTOSTERONE DERIVATIVE; TETRACYCLINE; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

CONGENITAL MALFORMATION; DIET SUPPLEMENTATION; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; HEALTH CARE PERSONNEL; HIGH RISK PREGNANCY; HUMAN; MATERNAL AGE; MATERNAL CARE; ORGANOGENESIS; PREGNANCY OUTCOME; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK ASSESSMENT; TERATOGENESIS; THERAPY EFFECT; TREATMENT CONTRAINDICATION;

ADULT; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MATERNAL WELFARE; NONPRESCRIPTION DRUGS; PHARMACEUTICAL PREPARATIONS; PRECONCEPTION CARE; PREGNANCY; PREGNANCY OUTCOME; TERATOGENS; WOMEN'S HEALTH;

EID: 57149114523     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.07.065     Document Type: Review

References (43)

1. Splinter M.Y., Sagraves R., Nightengale B., and Rayburn W.F. Pre-natal use of medications by women giving birth at a university hospital. South Med J 90 (1997) 498-502
2. Matt D.W., and Borzelleca J.F. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Witorsch R.J. (Ed). Reproductive toxicology. 2nd ed. (1995), Raven, New York 175-193
3. United States Department of Health and Human Services, Health Research Services Administration, Maternal and Child Health Bureau. Women's Health USA 2002. Rockville, Md: 2004.
4. Kochanek K.D., and Smith B.L. Deaths: preliminary data for 2002. National vital statistics reports; vol 52 no 13 (2004), National Center for Health Statistics, Hyattsville, Maryland
5. Czeizel A.E., Intödy Z., and Modell B. What proportion of congenital abnormalities can be prevented?. Br Med J 306 (1996) 499-503
6. Nielsen G.L., Norgaard B., Puho E., Rothman K.J., Sørensen H.T., and Czeizel A.E. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med 22 (2005) 693-696
7. Alexander S., Doods L., and Armson B.A. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol 92 (1998) 435-440
8. Sibai B.M. Chronic hypertension in pregnancy. Obstet Gynecol 100 (2002) 369-377
9. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep 55 (2006) 1-100 No. RR-11
10. Centers for Disease Control and Prevention. US Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. MMWR Morb Mortal Wkly Rep 51 RR18 (2002) 1-38
11. Czeizel A.E., and Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 327 (1992) 1832-1835
12. Czeizel A.E. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Gent 72 (1996) 179-183
13. Czeizel A.E. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. Br J Med 306 (1993) 1645-1648
14. Rutledge J.C. Developmental toxicity induced during early stages of mammalian embryogenesis. Mutat Res 396 (1997) 113-127
15. Brent R.L. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 1134 Suppl 4 (2004) 957-968
16. Uhl K. Conducting clinical pharmacology studies in pregnant and lactating women. In: Sahajwalla C.G. (Ed). New drug development: regulatory paradigms for clinical pharmacology and biopharmaceutics (2004), Marcel Dekker, Inc, New York 267-296
17. Lagoy C.T., Joshi N., Cragan J.D., and Rasmussen S.A. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health 14 (2005) 104-109
18. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee. Teratology 49 (1994) 446-447
19. Department of Health and Human Services, Food and Drug Administration. 21 CFR Part 201: content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Docket No. FDA 2006-0515. Federal Register Vol 73, No. 104, Page 4.
20. Briggs G.G., Freeman R.L., and Yaffee S.J. Drugs in pregnancy and lactation (Ref. ed.) (2002), Lippincott, Williams, and Wilkins, Philadelphia
21. Schwarz E.B., Jaselli J., Norton M., and Gonzales R. Prescription of teratogenic medications in United States ambulatory practices. Am J Med 118 (2005) 1240-1249
22. American Diabetes Association. Preconceptional care of women with diabetes. Diabetes Care 27 Suppl 1 (2004) S76-S78
23. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
24. American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 51 (1998) 944-948
25. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8 (2002) 457-469
26. Hirsh J., Fuster V., Ansell J., and Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41 (2003) 1633-1652
27. National Asthma Education and Prevention Program. Managing asthma during pregnancy: recommendations for pharmacologic treatment (2005), National Heart, Lung, and Blood Institute, Bethesda (MD)
28. Mahadevan U., and Kane S. American Gastroenterological Association Institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology 131 (2006) 278-282
29. Treatment of tuberculosis. MMWR Recomm Rep 52 RR-11 (2003) 1-77
30. Diamond M. Special treatment situations: menstrual migraine and menstrually-related migraine. Standards of care for headache diagnosis and treatment (2004), National Headache Foundation, Chicago (IL)
31. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 159 Suppl 4 (2002) 1-50
32. Committee on Drugs. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 105 (2000) 880-887
33. Paxil and the risk of birth defects. FDA Consumer 40 (2006) 4
34. Buitendijk S., and Bracken M.B. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 165 (1991) 33-40
35. Weler M.M., Mitchell A.A., and Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 45 (1992) 361-367
36. Radimer K., Bindewald B., Hughes J., Ervin B., Swanson C., and Picciano M.F. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160 (2004) 339-349
37. Ervin R.B., Wright J.D., and Reed-Gillette D. Prevalence of leading types of dietary supplements used in the Third National Health and Nutrition Examination Survey, 1988-94. Adv Data (2004) 1-7
38. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent trends in use of herbal and other natural products. Arch Intern Med 165 (2005) 281-286
39. Gardiner P., Graham R.E., Legedza A., Eisenberg D.M., and Phillips R.S. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166 (2006) 1968-1974
40. Barnes P.M., Powell-Griner E., McFann K., and Nahin R.L. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 343 (2004) 1-19
41. Pinn G., and Pallett L. Herbal medicine in pregnancy. Complement Ther Nurs Midwifery 8 (2002) 77-80
42. Cragan J.D., Friedman J.M., Holmes L.B., Uhl K., Green N.S., and Riley L. Ensure the safe and effective use of medications during pregnancy: planning and prevention through preconception care. Matern Child Health J 10 (2006) S129-S135
43. Black R.A., and Hill D.A. Over-the-counter medications in pregnancy. Am Fam Physician 67 (2003) 2517-2524